Holen Sie sich die Stockscreener-App
10.31
2.38%
0.24
Handel nachbörslich:
10.29
-0.02
-0.19%
Schlusskurs vom Vortag:
$10.07
Offen:
$10.04
24-Stunden-Volumen:
2.29M
Relative Volume:
0.94
Marktkapitalisierung:
$1.88B
Einnahmen:
$314.85M
Nettoeinkommen (Verlust:
$12.01M
KGV:
157.40
EPS:
0.0655
Netto-Cashflow:
$47.52M
1W Leistung:
-1.62%
1M Leistung:
+32.52%
6M Leistung:
+68.46%
1J Leistung:
+12.80%
1-Tages-Spanne:
$9.8401
$10.33
1-Wochen-Bereich:
$9.73
$10.55
52-Wochen-Spanne:
$5.25
$11.33
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
10.31 | 1.88B | 314.85M | 12.01M | 47.52M | 0.0655 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Form 4 Xeris Biopharma Holdings, Inc: Steven Pieper (Officer) For: 1 October - Investing.com Nigeria
Xeris Biopharma CFO Steven Pieper sells $47,036 in stock By Investing.com - Investing.com Canada
Xeris Biopharma CLO Beth Hecht sells $156,792 in XERS shares - Investing.com
Xeris Biopharma COO McCulloch sells $141,120 in shares - Investing.com
Insider Sell Alert: Beth Hecht Sells 16,666 Shares of Xeris Biop - GuruFocus
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
An officer plans a $159K share sale at Xeris Biopharma (XERS). - Stock Titan
Xeris Biopharma Holdings Insider Sold Shares Worth $250,000, According to a Recent SEC Filing - Yahoo Finance
A Xeris Biopharma (XERS) officer proposes a share sale valued at $637,000. - Stock Titan
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A 50% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial StrategySlideshow (NASDAQ:XERS) 2026-09-11 - Seeking Alpha
XERS Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus
Oppenheimer reiterates Xeris Pharmaceuticals stock rating on XP-8121 outlook - Investing.com Nigeria
Oppenheimer reiterates Xeris Pharmaceuticals stock rating on XP-8121 outlook - Investing.com Canada
Xeris Biopharma Holdings (NasdaqGS:XERS) Stock Forecast & Analyst Predictions - Simply Wall Street
symbol__ Stock Quote Price and Forecast - cnn.com
Xeris Biopharma Holdings, Inc. (XERS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xeris Biopharma Holdings, Inc. at XP-8121 Program Overview Transcript - GuruFocus
XERS Looks 54.7% Overvalued on GF Value™ as Clinical Update Appr - GuruFocus
Millions of thyroid patients may get weekly shot option from Xeris (NASDAQ: XERS) - Stock Titan
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism - businesswire.com
An estimated 3 to 5 million lack thyroid control. Xeris is developing a weekly injection. - Stock Titan
Xeris Biopharma Holdings Inc. (XERS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares By Investing.com - Investing.com South Africa
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock - Investing.com India
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock By Investing.com - Investing.com India
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares By Investing.com - Investing.com India
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares - Investing.com
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares By Investing.com - Investing.com Australia
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock By Investing.com - Investing.com Canada
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock By Investing.com - Investing.com Nigeria
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock By Investing.com - Investing.com Canada
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock - Investing.com
Xeris Biopharma CFO Steven Pieper Executes Sale of 5,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma CLO Beth Hecht Sells 16,666 Shares via 10b5-1 Trading Plan - kalkinemedia.com
Xeris Biopharma COO Kevin McCulloch Sells 15,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock By Investing.com - Investing.com Australia
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares By Investing.com - Investing.com UK
Xeris Biopharma Holdings Inc. (XERS) Peer Comparison – Compare with Others - Value Research
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock - Investing.com
Xeris Biopharma stock holds at $8.48 after earnings miss - ad-hoc-news.de
XERS Stock Price, Quote & News - Syfe
Xeris Biopharma Holdings Inc. (XERS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Xeris Biopharma Holdings, Inc. (0A8E.L) Stock Price, News, Quote & History - Yahoo Finance
Xeris Announces Details for XP-8121 Program Overview Webinar - Yahoo Finance
Xeris (XERS) Earnings Report: Profit Per Share Falls Below Its Benchmark in the Available Record; Price Reaction - vinanet.vn
XERS | Xeris Biopharma Holdings, Inc. FinancialsRevenue Breakdown - Quiver Quantitative
Xeris Biopharma CEO John Patrick Shannon Jr. Reports Share Withholding for RSU Tax Settlement - Kalkine Media
XERS Maintains Overweight Rating by Barclays -- Price Target Rai - GuruFocus
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS) - Seeking Alpha
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BETH HECHT | Officer |
Oct 01 '26 |
Proposed Sale |
9.56 |
16,666 |
159,327 |
0 |
| McCulloch Kevin | See Remarks |
Oct 01 '26 |
Sale |
9.41 |
15,000 |
141,120 |
1,599,208 |
| Hecht Beth | See Remarks |
Oct 01 '26 |
Sale |
9.41 |
16,666 |
156,792 |
1,111,130 |
| KEVIN MCCULLOCH | Officer |
Sep 28 '26 |
Proposed Sale |
9.10 |
70,000 |
637,000 |
0 |
| McCulloch Kevin | See Remarks |
Sep 28 '26 |
Sale |
10.00 |
25,000 |
250,000 |
1,614,208 |
| McCulloch Kevin | See Remarks |
Sep 01 '26 |
Sale |
8.49 |
15,000 |
127,308 |
1,639,208 |
| Pieper Steven | See Remarks |
Sep 01 '26 |
Sale |
8.50 |
5,000 |
42,500 |
1,356,053 |
| Hecht Beth | See Remarks |
Sep 01 '26 |
Sale |
8.49 |
16,666 |
141,434 |
1,127,796 |
| STEVEN PIEPER | Officer |
Aug 12 '26 |
Proposed Sale |
8.39 |
20,000 |
167,800 |
0 |
| Pieper Steven | See Remarks |
Aug 12 '26 |
Sale |
8.50 |
5,000 |
42,500 |
1,361,053 |
2.82%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):